HC Wainwright Increases Dianthus Therapeutics Price Target to $130

Analysts raise price target on biotech company's stock by 177%

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Analysts at HC Wainwright have increased their price target on Dianthus Therapeutics (NASDAQ:DNTH) from $47 to $130, representing a potential upside of 69.5% from the company's current stock price. The brokerage firm maintained its "buy" rating on the stock, citing positive developments in the company's Phase 3 CAPTIVATE trial for its lead drug candidate.

Why it matters

The significant increase in Dianthus Therapeutics' price target by a major investment firm signals growing optimism around the company's clinical pipeline and future growth prospects. As a clinical-stage biotech focused on developing complement therapeutics, Dianthus' progress is closely watched by investors seeking exposure to innovative drug development in the autoimmune and inflammatory disease space.

The details

In its research report, HC Wainwright highlighted Dianthus Therapeutics' recent announcement of an early "GO" decision in the Phase 3 CAPTIVATE trial for its lead drug candidate. The company was able to meet the responder criteria with fewer participants than originally planned, allowing it to move forward with the 300mg subcutaneous dose administered every two weeks while discussing the removal of the 600mg dose with regulators.

  • Dianthus Therapeutics announced the early "GO" decision in the Phase 3 CAPTIVATE trial on March 9, 2026.

The players

Dianthus Therapeutics

A clinical-stage biotechnology company developing complement therapeutics for patients with severe autoimmune and inflammatory diseases.

HC Wainwright

A full-service investment bank and securities trading firm that provides research coverage and investment banking services to public and private companies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The significant increase in Dianthus Therapeutics' price target by HC Wainwright underscores the growing optimism around the company's clinical pipeline and its potential to develop innovative therapies for autoimmune and inflammatory diseases. As Dianthus continues to advance its lead drug candidate through late-stage trials, investors will closely monitor the company's progress and any further updates from the investment community.